Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
medication
|
| gptkbp:activeDuring |
avanafil
|
| gptkbp:advertising |
promoted for quick action
|
| gptkbp:availability |
pharmacies and online
|
| gptkbp:brand |
gptkb:Stendra
|
| gptkbp:clinicalTrials |
erectile dysfunction treatment
studied in various populations recommended for erectile dysfunction |
| gptkbp:community_service |
available
|
| gptkbp:contraindication |
nitrates
severe cardiovascular disorders rare hearing loss rare priapism rare visual disturbances |
| gptkbp:date |
2012-04-27
|
| gptkbp:dosageForm |
tablets
|
| gptkbp:drugInterdiction |
true
oral bioavailability PDE5 inhibitor |
| gptkbp:duration |
up to 6 hours
|
| gptkbp:endOfLife |
5 hours
|
| gptkbp:hasCompetitors |
high with other ED drugs
|
| gptkbp:healthcare |
avoid alcohol
do not exceed recommended dose consult doctor if side effects occur take as needed |
| https://www.w3.org/2000/01/rdf-schema#label |
Stendra
|
| gptkbp:inheritsFrom |
15-30 minutes
|
| gptkbp:insuranceAccepted |
may vary by plan
|
| gptkbp:manufacturer |
Vivus,_Inc.
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:European_Union gptkb:United_States |
| gptkbp:name |
not on essential medicines list
|
| gptkbp:notableFeature |
gptkb:Levitra
Cialis Viagra |
| gptkbp:nutritionalValue |
CYP3A4
|
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
blister packs
|
| gptkbp:patentType |
yes
|
| gptkbp:publicPerception |
generally positive
|
| gptkbp:researchInterest |
ongoing for new indications
|
| gptkbp:route |
oral
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
dizziness
headache nasal congestion back pain flushing |
| gptkbp:skills |
100 mg
50 mg 200 mg |
| gptkbp:storage |
room temperature
|
| gptkbp:type |
false
|
| gptkbp:usedFor |
treatment of erectile dysfunction
|